New first-line therapy has transformed treatment for BRAF V600E–mutated metastatic colorectal cancer (mCRC), an aggressive subtype with historically poor outcomes. FDA approval of the triple combination—encorafenib, cetuximab, and mFOLFOX6—marks a major breakthrough for these patients.
The BREAKWATER trial demonstrated that this regimen doubled overall survival to 30.3 months compared with 15.1 months for standard therapy, while progression-free survival improved from 7.1 to 12.8 months. This confirms its effectiveness as a first-line option and establishes a new standard of care for this high-risk population.
The triple therapy works through complementary mechanisms: encorafenib inhibits the overactive BRAF V600E protein, cetuximab blocks EGFR to prevent resistance, and mFOLFOX6 chemotherapy delivers direct cytotoxic effects. By targeting multiple pathways simultaneously, this precision medicine approach significantly improves survival and disease control for patients with BRAF-mutated metastatic colorectal cancer.
窗体顶端
窗体底端